Antonio Jose Jimeno

Antonio Jose Jimeno's AcademicInfluence.com Rankings

Antonio Jose Jimeno

Philosophy

#8928

World Rank

#12409

Historical Rank

Logic

#5937

World Rank

#7399

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Antonio Jose Jimeno's Degrees

PhD Biomedical Sciences Johns Hopkins University
Doctorate Medicine Johns Hopkins University

Why Is Antonio Jose Jimeno Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Antonio Jose Jimeno's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses (2008) (3758)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Patient-derived tumour xenografts as models for oncology drug development (2012) (1048)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. (2008) (1004)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (2019) (871)
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy (2011) (701)
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. (2007) (691)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (454)
An In vivo Platform for Translational Drug Development in Pancreatic Cancer (2006) (427)
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. (2010) (416)
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. (2018) (381)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. (2015) (297)
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development (2009) (295)
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. (2017) (285)
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. (2009) (218)
Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer (2011) (208)
More than Markers: Biological Significance of Cancer Stem Cell-Defining Molecules (2010) (205)
Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. (2015) (192)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Head and Neck Cancers, Version 1.2015. (2015) (186)
Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma (2008) (179)
Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. (2016) (171)
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 (2014) (169)
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. (2022) (165)
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors (2012) (160)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (2019) (157)
HER 2 in gastric cancer : a new prognostic factor and a novel therapeutic target (2008) (149)
Head and Neck Cancers, Version 2.2014 (2014) (145)
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins (2013) (145)
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors (2013) (141)
Characterizing DNA methylation patterns in pancreatic cancer genome (2009) (138)
Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists (2006) (137)
Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. (2015) (135)
Bispecific antibodies for cancer therapy: A review (2017) (129)
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. (2009) (121)
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors (2017) (116)
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. (2008) (115)
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. (2014) (114)
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. (2010) (113)
Mycophenolate mofetil: An update. (2009) (112)
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer (2015) (109)
Fenugreek: A naturally occurring edible spice as an anticancer agent (2009) (106)
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. (2005) (104)
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors (2015) (101)
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer (2012) (101)
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia (2004) (98)
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer (2006) (97)
Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. (2012) (91)
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer (2009) (91)
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. (2008) (91)
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2 (2017) (90)
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy (2007) (89)
Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. (2013) (89)
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup (2014) (86)
Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors (2011) (86)
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (2011) (85)
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. (2013) (82)
Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base (2016) (81)
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. (2015) (77)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) (2016) (77)
Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. (2016) (76)
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer (2008) (76)
Molecular pathways in head and neck cancer: EGFR, PI3K, and more. (2013) (75)
Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. (2015) (74)
FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers (2015) (73)
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. (2005) (72)
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer (2010) (69)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer (2010) (68)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial (2018) (68)
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. (2015) (67)
Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. (2017) (67)
The intersection between cannabis and cancer in the United States. (2012) (66)
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. (2008) (62)
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma (2015) (61)
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours (2013) (57)
New phosphatidylinositol 3-kinase inhibitors for cancer (2011) (55)
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. (2017) (55)
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer (2012) (55)
Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. (2014) (54)
ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/β-Catenin, Notch and PI3K/Akt Signaling Pathways (2015) (53)
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer (2013) (50)
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. (2006) (50)
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. (2021) (49)
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors (2018) (48)
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies (2014) (48)
Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells (2020) (47)
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. (2007) (47)
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer (2018) (47)
A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer (2010) (46)
Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study. (2006) (45)
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts (2009) (45)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2015) (45)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2015) (44)
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. (2017) (44)
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors (2008) (44)
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors (2015) (43)
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor (2018) (43)
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. (2006) (41)
Benzoylphenylurea sulfur analogues with potent antitumor activity. (2006) (40)
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies (2012) (39)
Wnt signaling dynamics in head and neck squamous cell cancer tumor‐stroma interactions (2018) (39)
Belinostat for the treatment of peripheral T-cell lymphomas. (2014) (38)
Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis (2005) (38)
Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. (2010) (36)
Ephrin‐B2 overexpression predicts for poor prognosis and response to therapy in solid tumors (2017) (35)
Multitargeted therapy: can promiscuity be praised in an era of political correctness? (2006) (34)
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay (2009) (34)
C-fos assessment as a marker of anti-epidermal growth factor receptor effect. (2006) (34)
The development of regorafenib and its current and potential future role in cancer therapy. (2013) (33)
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer (2009) (33)
Eribulin: Rediscovering Tubulin as an Anticancer Target (2009) (33)
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. (2017) (33)
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer (2007) (32)
Assessment of celecoxib pharmacodynamics in pancreatic cancer (2006) (32)
Atrasentan: targeting the endothelin axis in prostate cancer (2004) (32)
Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). (2011) (32)
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer (2016) (31)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors (2008) (30)
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors (2004) (29)
Disseminated intravascular coagulopathy in aortic aneurysms. (2005) (29)
Integration of panitumumab into the treatment of colorectal cancer. (2010) (28)
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer (2005) (28)
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (2016) (28)
A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (28)
Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice (2013) (27)
Cancer Stem Cells in Squamous Cell Carcinoma. (2017) (27)
MCP-1 in urine as biomarker of disease activity in Systemic Lupus Erythematosus. (2012) (27)
A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (2011) (27)
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (2006) (26)
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. (2020) (26)
1042ODurvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study (2017) (26)
Blockade of epidermal growth factor receptor (EGFR) activity. (2005) (26)
JAK2 inhibition for the treatment of hematologic and solid malignancies (2012) (26)
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer (2008) (26)
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. (2016) (26)
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas (2013) (25)
Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. (2019) (25)
Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma (2004) (25)
Emerging from their burrow: Hedgehog pathway inhibitors for cancer (2016) (25)
A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. (2016) (24)
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (2012) (23)
Inter‐ and intra‐tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas (2019) (22)
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck (2014) (22)
A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors. (2014) (22)
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma (2016) (21)
A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. (2012) (21)
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. (2009) (21)
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays (2007) (21)
FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation (2017) (21)
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. (2010) (21)
DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation (2015) (20)
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer (2007) (20)
Radiation recall dermatitis induced by pegylated liposomal doxorubicin. (2003) (20)
Dabrafenib in the treatment of advanced melanoma. (2013) (20)
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (2015) (19)
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors (2020) (19)
Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins (2014) (19)
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas (2016) (18)
Phase II trial of dose‐dense paclitaxel, cisplatin, 5‐fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck (2004) (18)
Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression (2018) (18)
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. (2014) (18)
Olaparib for the treatment of ovarian cancer. (2016) (18)
Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers (2018) (18)
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. (2010) (18)
Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors. (2013) (17)
Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125 (2008) (17)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2016) (17)
Macrophages Promote Growth of Squamous Cancer Independent of T cells (2019) (16)
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. (2018) (16)
986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT). (2014) (15)
Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer (2018) (15)
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC (2020) (15)
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors (2007) (15)
Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. (2009) (14)
Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors. (2013) (14)
Vemurafenib: the road to personalized medicine in melanoma. (2012) (14)
Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. (2013) (14)
Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts (2021) (13)
Prolonged standard treatment for systemic lupus erythematosus fails to normalize the secretion of innate immunity-related chemokines. (2010) (13)
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors (2017) (13)
Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. (2018) (13)
Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. (2008) (12)
A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA) (2008) (12)
Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. (2018) (12)
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration (2006) (12)
Axitinib, a new therapeutic option in renal cell carcinoma. (2012) (12)
Stereotactic Body Radiotherapy as Primary Therapy for Head and Neck Cancer in the Elderly or Patients with Poor Performance (2014) (12)
Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. (2013) (12)
Phase II trial of vinorelbine tartrate in patients with treatment-naïve metastatic melanoma (2005) (12)
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. (2007) (11)
Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. (2006) (11)
Trametinib for the treatment of melanoma. (2013) (11)
Generation of functional human thymic cells from induced pluripotent stem cells. (2021) (11)
The humanized mouse: Emerging translational potential (2020) (11)
Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. (2013) (11)
In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent (2005) (11)
Atrasentan: a rationally designed targeted therapy for cancer. (2006) (10)
Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function. (2019) (10)
Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy (2005) (10)
Idelalisib for the treatment of indolent non-Hodgkin's lymphoma. (2014) (10)
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (2011) (10)
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule (2017) (10)
Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies (2020) (10)
Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer. (2016) (9)
BRCA in breast cancer: from risk assessment to therapeutic prediction. (2009) (9)
Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy (2018) (9)
[MCP-1 in urine as biomarker of renal lupus in absence of cytokines, interferon-γ and growth factors]. (2010) (9)
Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma. (2020) (9)
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer (2008) (9)
Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer (2016) (9)
Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. (2016) (9)
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers (2021) (9)
MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma (2019) (9)
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. (2014) (8)
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors (2022) (8)
Crizotinib for the treatment of patients with advanced non-small cell lung cancer. (2012) (8)
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma (2021) (8)
Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer. (2015) (8)
Strategies for suppressing angiogenesis in gynecological cancers. (2007) (7)
Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. (2015) (7)
PX-866 and docetaxel in patients with advanced solid tumors. (2012) (7)
Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). (2019) (7)
Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine. (2009) (6)
Tivozanib: practical implications for renal cell carcinoma and other solid tumors. (2013) (6)
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study (2021) (6)
Metastatic Colorectal Cancer: Focus on Panitumumab (2010) (6)
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck. (2014) (5)
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer (2021) (5)
Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors. (2020) (5)
Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade (2019) (5)
Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). (2014) (5)
Vismodegib in basal cell carcinoma. (2012) (5)
An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases (2015) (5)
Induction Chemotherapy Predicts Cumulative Radiation Dose and Fails to Improve Survival in Advanced Head and Neck Cancer, a National Cancer Data Base Analysis (2016) (4)
Avapritinib for metastatic or unresectable gastrointestinal stromal tumors. (2020) (4)
Capmatinib for non-small cell lung cancer. (2021) (4)
A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors (2016) (4)
γ-secretase inhibitors in solid tumor malignancies (2011) (4)
Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment (2007) (4)
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft (2020) (4)
Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) (2017) (4)
NCI-60 gene set connectivity map (GS-CMAP): Connecting pathway-based gene expression profiles for therapeutic efficacy determination (2008) (4)
Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC). (2010) (4)
Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer (2007) (3)
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC (2022) (3)
In vivo platform for translational drug development and biomarker discovery in pancreatic cancer. (2006) (3)
Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101. (2021) (3)
SP-0298: Phase I Results of PARPi (Olaparib) + RT + Cetuximab in LAHNSCC (2016) (3)
Safety and Feasibility Update of Olaparib, an Orally Bioavailable PARP Inhibitor, With Concurrent Cetuximab and Radiation Therapy in Heavy Smokers With Stage III-IVB Squamous Cell Carcinoma of the Head/Neck: A Phase 1 Trial (2014) (3)
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma. (2016) (3)
Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors. (2011) (3)
Inhibition of MK2 Decreases Inflammatory Cytokine Production and Tumor Volumes in HPV-Positive and HPV-Negative Models of Head and Neck Squamous Cell Carcinoma (2018) (3)
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. (2008) (3)
Abstract 652: PI3K inhibition combined with either cetuximab or docetaxel in a direct patient tumor model of HPV-positive and negative head and neck cancers (2011) (3)
A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors. (2013) (3)
353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC (2020) (3)
Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. (2011) (3)
A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent/Metastatic (R/M) Head-and-Neck Squamous Cell Carcinoma (2014) (3)
A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. (2015) (3)
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. (2020) (3)
Biologically based treatment in head and neck squamous cell carcinoma (HNSCC) (2012) (3)
Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors (2012) (3)
Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia (2006) (3)
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies (2022) (2)
Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model (2016) (2)
Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors. (2013) (2)
Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. (2013) (2)
Pharmacodynamic Studies in Early Phase Drug Development (2011) (2)
Dose and Dose Intensity Effect of Adjuvant Anthracycline-Based Chemotherapy in Early Breast Cancer: A Retrospective Analysis (2004) (2)
Phase I study of oral rigosertib in patients with advanced solid tumors. (2012) (2)
Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of rapamycin in adult patients with solid tumors. (2006) (2)
Data and text mining Text processing through Web services : calling Whatizit (2008) (2)
A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa) (2008) (2)
Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma. (2020) (2)
Predictive Biomarkers and Personalized Medicine Tumor Engraftment in Nude Mice and Enrichment in Stroma-Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer (2011) (2)
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity (2005) (2)
Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. (2019) (2)
539 Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ, for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma (2021) (2)
48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors (2021) (2)
989PDPHASE 1B STUDY OF MEHD7945A (MEHD) PLUS CISPLATIN/FLUOROURACIL (CIS/5FU) OR CARBOPLATIN/PACLITAXEL (CARBO/PAC) FOR 1ST-LINE TREATMENT OF RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (RMSCCHN). (2014) (2)
EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials (2012) (1)
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers (2021) (1)
Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies-Final results. (2006) (1)
In vivo testing of Mycophenolic acid (MPA) in primary pancreatic cancer (PaCa) xenografts (2007) (1)
TG-101348: Tyrosine-protein kinase JAK2 inhibitor receptor-type tyrosine-protein kinase FLT3 inhibitor treatment of myeloproliferative diseases (2011) (1)
23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors (2014) (1)
Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia (2004) (1)
The endothelin pathway and its modulation in prostate cancer (2016) (1)
430 Phase I and pharmacokinetic study of UCN-01 (U) in combination with irinotecan (I) in patients with solid tumors (2004) (1)
Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. (2021) (1)
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (2016) (1)
Changes in FDG-PET in response to rapamycin (R) correlated with Akt pathway inhibition and not with clinical outcome (2008) (1)
366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase (2010) (1)
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies (2022) (1)
Phase 1b Study of MEHD7945A (DULIGOTUZUMAB) Plus Cisplatin/Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (2014) (1)
Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome-proliferator activated receptor gamma receptors expression. (2010) (1)
Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell‐like properties and phosphoinositide 3‐kinase inhibitor insensitivity (2022) (1)
A phase I and pharmacokinetic study of a weekly dosing schedule of paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors. (2014) (1)
Management of metastatic breast cancer: are we prepared to cope with our own success? (2004) (1)
Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. (2013) (1)
A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A. (2019) (1)
Abstract 5000: The functional stem cell marker aldehyde dehydrogenase enhances pancreatic cancer stem cell isolation and correlates with clinical prognosis (2008) (1)
Development of core competencies in drug development in medical oncology: An unexplored field (2008) (1)
Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma (2009) (1)
Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (1)
Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma. (2021) (1)
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies. (2018) (1)
Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel. (2011) (1)
Reply to B. Freidlin et al. (2014) (1)
Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. (2012) (1)
Survival Impact of Local Therapy for Thyroid Carcinoma: A Surveillance, Epidemiology, and End Results Analysis (2016) (0)
FDG-PET in mTOR inhibitor therapy (mTOR Rx): A study of the relationship between Akt/mTOR and glycolytic pathways (2008) (0)
Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors (2021) (0)
Abstract 5035: Blockade of EphB4-ephrin-B2 interaction remodels the tumor immune microenvironment in head and neck cancers (2019) (0)
CXCR4 activation mediates resistance to mTOR-directed therapy via regulation of VHL (2007) (0)
Migration of Head and Neck Squamous Cell Cancer Cells is Dependent on Tenascin-C Expression (2016) (0)
351 C-fos mRNA levels predict response to Iressa therapy (2004) (0)
Preliminary Safety and Tolerability of a Phase 1 Trial of Olaparib in Combination With Cetuximab and Radiation Therapy in Heavy Smokers With Locally Advanced, Stage IVA-B Squamous Cell Carcinoma of the Head/Neck (2014) (0)
Prognostic value of breast cancer m-RNA transcripts (Ts) detection by RT-PCR in GCSF stimulated peripheral blood (PB) after adjuvant chemotherapy (ACT) in high-risk breast cancer patients (HRBCP) (2005) (0)
Race, gender and mutations in the prediction of anti-EGFR activity. (2005) (0)
Predicting outcomes in patients with advanced malignancies treated on Phase 1 clinical trials. (2015) (0)
187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours (2021) (0)
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors (2020) (0)
Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. (2006) (0)
Therapeutic effect of inhibiting nonsense mediated decay in human cancers with TP53 premature termination codons (2006) (0)
Abstract IA04: Novel approaches to study the tumor-stroma interaction and translate immune-directed therapies (2020) (0)
Radiation Dose Uncertainty in a Mouse Head and Neck Irradiation Model (2014) (0)
Larynx and Esophageal Inlet Sparing Expedites Recovery from Dysphagia and Feeding Tube Removal in Patients with Stage III-IV Oropharyngeal Squamous Cell Carcinoma Treated with IMRT (2011) (0)
Role of EphB4 in Radiosensitization of Head and Neck Squamous Cell Carcinoma (2016) (0)
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma (2021) (0)
Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. (2004) (0)
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors (2023) (0)
Abstract #4702: Pathway-based comparison approach for the identification of responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC) (2009) (0)
The XactMice: A Xenochimaeric Mouse with Tumor and Hematopoietic System Obtained from the Same Patient (2011) (0)
Eribulin : RediscoveringTubulin as an Anticancer Target 55 (2009) (0)
Title : The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas (2013) (0)
183P COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors (2022) (0)
Abstract IA14: PDX models in head and neck cancers: Present status and future application for immune-oriented biology and therapy development (2016) (0)
Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial. (2016) (0)
Optimizing targeted agents development in pancreatic cancer: A fine-needle aspirate biopsy (FNAB) based ex vivo and in vivo assay. (2006) (0)
638 COMMANDER-001: a phase 1/2, first-in-human, multicenter, open label study of SQZ-eAPC-HPV as monotherapy and with pembrolizumab in patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors (trial in progress) (2022) (0)
Generation of functional thymic organoids from human pluripotent stem cells (2023) (0)
Abstract 3263: Evaluation of the activity of rigosertib, an inhibitor of PI3K and MAPK pathways, in a preclinical model of colorectal cancer. (2013) (0)
Abstract 4169: Inhibition of EphB4-ephrin-B2 signaling results in enhanced sensitivity to cetuximab-radiation therapy in head and neck cancers (2018) (0)
Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors. (2010) (0)
Design, synthesis and evaluation of microtubule inhibitors phenoxy pyridine (PP) and phenyl sulfanyl pyridine (PSP) analogs for cancer therapy (2007) (0)
Does Age Matter? Survival Outcomes With the Addition of Concurrent Chemotherapy for Elderly Head and Neck Cancer Patients Undergoing Definitive Radiation Using the National Cancer Data Base (2016) (0)
Panitumumab in the treatment of colon cancer: A biomarker dilemma. (2014) (0)
Monographs: Tivozanib: practical implications for renal cell carcinoma and other solid tumors. (2013) (0)
Combined EGFR targeted therapy in a novel in vivo pancreas cancer model (2007) (0)
Developing a novel method for predicting tumor responses to drug combination based on pathway expression signatures (2008) (0)
Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma. (2003) (0)
Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer (2014) (0)
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a small molecule inhibitor of Src/Abl, in human pancreatic tumor xenografts (2007) (0)
MK2 Pathway Mediates Radiation-Induced Tumor Inflammation and Is a Poor Prognostic Factor in Head and Neck Cancer (2018) (0)
The importance of KRAS status in managing metastatic colorectal cancer (2009) (0)
Individualizing therapy using direct xenografting of pancreas cancers: a multi-modality approach (2006) (0)
316 Cetuximab-induced clearance of the epidermal growth factor receptor (EGFR) overcomes resistance of cancer cells to EGFR tyrosine kinase (TK) inhibitors (2004) (0)
The Hedgehog Pathway Modulates Radiation Therapy Resistance in Head-and-Neck Cancer (2013) (0)
Locoregional recurrence of an HPV-positive squamous cell carcinoma of the head and neck. (2011) (0)
Abstract IA07: Head and neck squamous cell cancer stem cells: Harnessing oncogenic signaling to enable tumorigenicity (2017) (0)
Use of amolecular mimicry approach to identify effective agents in pancreatic cancer. (2009) (0)
Abstract A76: Efficacy of immunotherapy agents in patients with metastatic breast cancer treated in phase I clinical trials (2020) (0)
Novel in vivo model for drug development in pancreas cancer (2005) (0)
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer. (2023) (0)
Epidermal Growth Factor Receptor Inhibition in Non–Small Cell Lung Cancer (2007) (0)
Abst Intro The cus of the pa tologi from initiat and C nocom to gen the re the or cell ( which proge eratin theory (2010) (0)
Coordinated over-expression of genes in the EGFR pathway predicts sensitivity to EGFR inhibition in pancreatic cancer (2007) (0)
Cancer Therapy : Preclinical Personalized Chemotherapy Pro fi ling Using Cancer Cell Lines from Selectable Mice (2013) (0)
Which side is better? The impact of primary tumor side in early stage colorectal cancer (CRC). (2017) (0)
Enhanced Therapeutic Radiosensitization by Targeting EphB4 Receptor in Head and Neck Squamous Cell Carcinoma (2016) (0)
Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development. (2009) (0)
Small Molecule Therapeutics The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas (2013) (0)
Single nucleotide polymorphisms of TSER, ATM, RecQ1 genes association with survival in pancrease cancer. (2009) (0)
191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors (2022) (0)
Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients (2011) (0)
From the Sea to the Clinic : from Halichondrin B to Eribulin Mesylate (2009) (0)
Early prediction of antiepidermal growth factor receptor therapy with 18[F]FDG-PET: A preclinical and clinical correlation. (2007) (0)
Reviewers for Cellular Oncology in 2008 (2009) (0)
767 Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma (2022) (0)
Wednesday, 22 October 2008Poster SessionsBiomarkers77 POSTER Prediction and in vivo validation of AZD0530 sensitivity by gene expression profiling in human pancreatic tumor xenografts (2008) (0)
Early prediction of anti-epidermal growth factor receptor (EGFR) therapy with 18[F]FDG-PET: A preclinical and clinical correlation (2007) (0)
P14.05 Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors (2021) (0)
Novel Agents and Paradigms in Development in HNSCC (2012) (0)
Identification of diagnostic and therapeutic targets of pancreatic cancer using proteomic approaches (2009) (0)
Rapamycin induced "stunning" on FDG PET/CT in pancreatic cancer (2008) (0)
Abstract LB-127: Role of EphB4 in radiosensitization of head and neck squamous cell carcinoma (2016) (0)
Management of Locally Advanced and Recurrent Pancreas Cancer (2008) (0)
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors (2022) (0)
Hedgehog Pathway Mediates Head/Neck Radiation Resistance and Tumor Repopulation (2014) (0)
Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC (2022) (0)
Advances in the Treatment of Colorectal Cancer: Targeting Receptors of Disease (2009) (0)
Title : Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Antonio Jose Jimeno?

Antonio Jose Jimeno is affiliated with the following schools:

McGill University
Manipal Academy of Higher Education
University of Colorado Denver
Baylor College of Medicine
University of Colorado
Johns Hopkins University